Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nina Seborowski

Neurology Rockville, MD Medical Doctor

NPI 1174731137 CMS profile 994967

11125 Rockville Pike, Suite # 307, Rockville, MD 20852

Open in the dashboard

General payments

$3,551

170 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nina Seborowski of Rockville, MD is reported in the CMS Open Payments database as having received $3,551 across 170 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $441 15
2024 General $574 29
2023 General $520 17
2022 General $526 21
2021 General $600 43
2020 General $410 21
2019 General $479 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nina Seborowski
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Nina Seborowski were reported at $441. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Nina Seborowski Neurology median Middle half National median
2019 $479 $474 $118–$2,177 $163
2020 $410 $367 $82–$2,309 $114
2021 $600 $438 $104–$2,547 $132
2022 $526 $442 $103–$2,388 $149
2023 $520 $464 $119–$2,312 $160
2024 $574 $468 $119–$2,323 $164
2025 $441 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Tris Pharma Inc $1,326 49 payments
  2. Corium, Inc. $380 13 payments
  3. Novo Nordisk Inc $290 14 payments
  4. kaleo, Inc. $287 16 payments
  5. Adlon Therapeutics L.P. $260 17 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $246 12 payments
  7. Supernus Pharmaceuticals, Inc. $132 16 payments
  8. Cranial Technologies, Inc $120 9 payments
  9. Ironshore Pharmaceuticals Inc. $107 4 payments
  10. ALK-Abello, Inc $81 3 payments
  11. Other $320 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,551 170 payments
Products named General payments · program years 2019–2025
  1. Dyanavel XR Adhd $725 20 payments
  2. Dyanavel XR Adhd $535 25 payments
  3. Azstarys $380 13 payments
  4. Quillivant Adhd $355 4 payments
  5. Quillichew ER Adhd $338 3 payments
  6. AUVI-Q $287 16 payments
  7. ADHANSIA XR $260 17 payments
  8. Quillichew ER Adhd $238 2 payments
  9. Quillivant Adhd $238 2 payments
  10. VYVANSE $226 11 payments
  11. Other $1,447 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

170 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record